Glenmark signs cancer drug licensing deal with China's Hengrui for $18 million upfront with $1.1 billion in milestone payments

Glenmark obtains exclusive rights to develop and commercialize Trastuzumab Rezetecan (SHR-A1811) for several emerging markets.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Glenmark Pharmaceuticals, through one of its subsidiaries, has boosted its oncology pipeline by signing an exclusive licensing pact with China's Hengrui Pharma for its antibody drug conjugate (ADC) to be sold in emerging markets, a company filing said on September 24.

The ADC, Trastuzumab Rezetecan, was approved in China to treat adult patients in some cases of locally advanced lung cancer. An antibody drug conjugate (ADC) is a cancer treatment that combines a monoclonal antibody, a linker, and a cytotoxic drug.

The deal involves an upfront payment of $18 million by the subsidiary of Glenmark Pharma - Glenmark Specialty SA - and Hengrui will be eligible for regulatory and milestone payments of up to $1.093 billion.

"This partnership aligns strongly with our strategy to bring differentiated, high-value therapies to patients," Glenn Saldanha, CMD, Glenmark Pharma said, adding that the deal expands the company's oncology pipeline.

Hengrui said the deal hold the promise to be expanded to more regions, going forward. "This collaboration with Glenmark is a significant step in Hengrui’s ongoing strategy to deepen its presence in emerging markets. We look forward to working together to enhance the accessibility of innovative therapies and to bring new hope to patients in more countries and regions,” said Jo Feng, President of Hengrui Pharma.

The collaboration is a significant step in Glenmark’s oncology strategy and reinforces the commitment to deliver next-generation therapies across underserved geographies.